AstraZeneca Plc (AZN)

37.33
0.16 0.43
NYSE : Health Technology
Prev Close 37.17
Open 37.16
Day Low/High 36.97 / 37.37
52 Wk Low/High 28.43 / 37.30
Volume 3.63M
Avg Volume 3.67M
Exchange NYSE
Shares Outstanding 2.53B
Market Cap 91.61B
EPS 1.20
P/E Ratio 16.44
Div & Yield 1.37 (3.69%)

Latest News

Biogen Shares Soar on Positive Alzheimer's Drug Results

Biogen Shares Soar on Positive Alzheimer's Drug Results

The company's drug showed promising results versus a placebo in a Phase 2 trial.

FARXIGA In Combination With ONGLYZA Demonstrates Similar Glycemic Control With Additional Benefits Vs. Insulin Glargine In Patients With Type 2 Diabetes

FARXIGA In Combination With ONGLYZA Demonstrates Similar Glycemic Control With Additional Benefits Vs. Insulin Glargine In Patients With Type 2 Diabetes

AstraZeneca (NYSE: AZN) presented key data on the use of FARXIGA ® (dapagliflozin) in diverse patient populations with type 2 and type 1 diabetes (T2D, T1D) at the American Diabetes Association (ADA) 78th Scientific Sessions this week in Orlando, FL, June...

AstraZeneca To Share Latest Data From An Industry-Leading Portfolio That Aims To Advance Clinical Understanding Of Diabetes And CV Risk Management At ADA 2018

AstraZeneca To Share Latest Data From An Industry-Leading Portfolio That Aims To Advance Clinical Understanding Of Diabetes And CV Risk Management At ADA 2018

AstraZeneca and its global biologics research and development arm, MedImmune, will present 45 abstracts including seven late-breaking data disclosures from the Company's Cardiovascular (CV), Renal and Metabolism (CVRM) therapy area at the American...

Latest Reasons to Avoid Alzheimer's Plays

Latest Reasons to Avoid Alzheimer's Plays

Eli Lilly, AstraZeneca and vTv Therapeutics show why it's best to stay away from biotech's black hole.

Eli Lilly, AstraZeneca Shares Fall After Halting Alzheimer's Drug Test

Eli Lilly, AstraZeneca Shares Fall After Halting Alzheimer's Drug Test

The biopharmaceutical companies saw their stocks drop amid fallout of failed Alzheimer's drug trials.

Stocks Mixed After Trump-Kim Summit, Wall Street Looks to Fed Meeting

Stocks Mixed After Trump-Kim Summit, Wall Street Looks to Fed Meeting

Stocks finished mixed on Tuesday, following the summit between Donald Trump and North Korean leader Kim Jong Un and as Wall Street turns its attention the start of the Federal Reserve's two-day meeting.

Jim's Daily Rundown

Jim discusses our Salesforce buy, Eli Lilly, UnitedHealth and Cimarex and also answers a club member's question!

Peace Hopes Weigh on Defense Stocks

Shares of defense stocks slide after Trump meets Kim.

Trump Meets Kim, AT&T and Time Warner, McDonald's - 5 Things You Must Know

Trump Meets Kim, AT&T and Time Warner, McDonald's - 5 Things You Must Know

U.S. stock futures trade lower after a signed agreement between Donald Trump and North Korean leader Kim Jong Un offers few specifics on denuclearization of the Korean peninsula; a ruling on the AT&T and Time Warner merger is expected Tuesday; McDonald's reportedly to detail its restructuring plan.

Biotech Bargains: Two Cheap Small-Cap Stocks in an Exciting Sector

Biotech Bargains: Two Cheap Small-Cap Stocks in an Exciting Sector

I continue to see these names as bargains in the biotech and biopharma space.

Seroquel Stepping Stone: How Luye Will Use Seroquel To Expand In Emerging Markets

Seroquel Stepping Stone: How Luye Will Use Seroquel To Expand In Emerging Markets

SHANGHAI, June 6, 2018 /PRNewswire/ -- The $538 million acquisition by Luye Pharma Group Ltd.

Small Cap Biotech Bargains

Small Cap Biotech Bargains

Here are 2 small caps I continue to see as bargains in this space.

Nektar Therapeutics Just Lost More Than $6 Billion in Value Because of One Drug

Nektar Therapeutics Just Lost More Than $6 Billion in Value Because of One Drug

Nektar Therapeutics shares got destroyed on Monday. Here is why.

Moxetumomab Pasudotox Pivotal Data In Patients With Previously-Treated Hairy Cell Leukemia Presented At The 2018 ASCO Meeting

Moxetumomab Pasudotox Pivotal Data In Patients With Previously-Treated Hairy Cell Leukemia Presented At The 2018 ASCO Meeting

AstraZeneca and MedImmune, its global biologics research and development arm, today presented results from the Phase III ('1053') clinical trial (Abstract #7004) that evaluated moxetumomab pasudotox in 80 patients with relapsed or refractory hairy cell...

IMFINZI® (Durvalumab) Significantly Improves Overall Survival In The Phase III Pacific Trial For Unresectable Stage III Non-Small Cell Lung Cancer

IMFINZI® (Durvalumab) Significantly Improves Overall Survival In The Phase III Pacific Trial For Unresectable Stage III Non-Small Cell Lung Cancer

AstraZeneca and MedImmune, its global biologics research and development arm, today announced positive overall survival (OS) results for the Phase III PACIFIC trial, a randomized, double-blinded, placebo-controlled, multi-center trial of IMFINZI ®...

AstraZeneca Heads To 2018 ASCO Annual Meeting With Its Diversified Oncology Portfolio And Next-Generation Pipeline

AstraZeneca Heads To 2018 ASCO Annual Meeting With Its Diversified Oncology Portfolio And Next-Generation Pipeline

AstraZeneca and MedImmune, its global biologics research and development arm, head to the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL, June 1-5, 2018, with an expanded portfolio in Oncology.

LOKELMATM Approved In The US For The Treatment Of Adults With Hyperkalemia

LOKELMATM Approved In The US For The Treatment Of Adults With Hyperkalemia

AstraZeneca (NYSE: AZN) today announced that the US Food and Drug Administration (FDA) has approved LOKELMA TM (sodium zirconium cyclosilicate), formerly ZS-9, for the treatment of hyperkalemia in adults.

LOKELMATM Approved In The US For The Treatment Of Adults With Hyperkalemia

LOKELMATM Approved In The US For The Treatment Of Adults With Hyperkalemia

AstraZeneca (NYSE: AZN) today announced that the US Food and Drug Administration (FDA) has approved LOKELMA TM (sodium zirconium cyclosilicate), formerly ZS-9, for the treatment of hyperkalemia in adults.

4 Great Dividend Stocks That Always Remember to Say 'Thank You': Market Recon

4 Great Dividend Stocks That Always Remember to Say 'Thank You': Market Recon

These dividend payers compete in businesses that I'm interested in and believe in -- and they pay me to own the shares.

Watch Oncology Stocks Ahead of 2 Big Events

Watch Oncology Stocks Ahead of 2 Big Events

Data and industry conferences will likely be catalysts for shares in the space.

3 Potential Biotech Buyout Targets in the Second Quarter

3 Potential Biotech Buyout Targets in the Second Quarter

Novartis' deal for AveXis has ignited a rally in other gene-therapy concerns.

Possible Biotech Takeout Plays

Possible Biotech Takeout Plays

A look at possible second-quarter M&A activity in the biotech sector.

US FDA Approves BYDUREON For Use With Basal Insulin In Patients With Type 2 Diabetes With Inadequate Glycemic Control

US FDA Approves BYDUREON For Use With Basal Insulin In Patients With Type 2 Diabetes With Inadequate Glycemic Control

AstraZeneca today announced the US Food and Drug Administration (FDA) has approved BYDUREON ® (exenatide extended-release) for injectable suspension as an add-on therapy to basal insulin in adults with type 2 diabetes...

US FDA Accepts Biologics License Application For Moxetumomab Pasudotox In Hairy Cell Leukemia

US FDA Accepts Biologics License Application For Moxetumomab Pasudotox In Hairy Cell Leukemia

AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for moxetumomab pasudotox, an...

AstraZeneca Presents New Data Evaluating Safety And Efficacy Of FARXIGA In Patients With Type 2 Diabetes And Moderate Renal Impairment

AstraZeneca Presents New Data Evaluating Safety And Efficacy Of FARXIGA In Patients With Type 2 Diabetes And Moderate Renal Impairment

AstraZeneca today announced the results of DERIVE, a Phase 3 study that evaluated the efficacy and safety of FARXIGA ® (dapagliflozin 10 mg), in patients with type 2 diabetes (T2D) with moderate renal impairment...

AstraZeneca Announces Renewed Recommendation And Availability Of FLUMIST QUADRIVALENT Vaccine In The US

AstraZeneca Announces Renewed Recommendation And Availability Of FLUMIST QUADRIVALENT Vaccine In The US

AstraZeneca today announced that the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) has voted in favor of a renewed recommendation for the use of FLUMIST ®...

TheStreet Quant Rating: B (Buy)